Asset Details
Do you wish to reserve the book?
Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
Do you wish to request the book?
Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
2025
Overview
Taxanes and platinum molecules, specifically paclitaxel and carboplatin, are widely used anticancer drugs that induce cell death and serve as first‐line chemotherapy for various cancer types. Despite the efficient effect of both drugs on cancer cell proliferation, many tumours have innate resistance against paclitaxel and carboplatin, which leads to inefficient treatment and poor survival rates. Haploid human embryonic stem cells (hESCs) are a novel and robust platform for genetic screening. To gain a comprehensive view of genes that affect or regulate paclitaxel and carboplatin resistance, genome‐wide loss‐of‐function screens in haploid hESCs were performed. Both paclitaxel and carboplatin screens have yielded selected plausible gene lists and pathways relevant to resistance prediction. The effects of mutations in selected genes on the resistance to the drugs were demonstrated. Based on the results, an algorithm that can predict resistance to paclitaxel or carboplatin was developed. Applying the algorithm to the DNA mutation profile of patients' tumours enabled the separation of sensitive versus resistant patients, thus, providing a prediction tool. As the anticancer drugs arsenal can offer alternatives in case of resistance to either paclitaxel or carboplatin, an early prediction can provide a significant advantage and should improve treatment. The algorithm assists this unmet need and helps predict whether a patient will respond to the treatment and may have an immediate clinically actionable application. To gain a comprehensive view of genes that affect the anticancer drugs paclitaxel and carboplatin resistance, genome‐wide loss‐of‐function screens in haploid hESCs were performed. The screens yielded selected plausible gene lists and pathways relevant to drug resistance, and an algorithm that can predict resistance to paclitaxel or carboplatin was developed.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
